Methods & Noninvasive PK Study to Improve Iontophoresis

方法

• 批准号: 6942537
• 负责人: Kevin S. Li
• 金额: $ 4.4万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-15 至 2005-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6942537
• 关键词: clinical research; conjunctiva; drug administration routes; drug delivery systems; electroretinography; eye; eye disorder; eye pharmacology; human subject; imaging /visualization /scanning; iontophoresis therapy; laboratory rabbit; macular degeneration; magnetic resonance imaging; nonhuman therapy evaluation; passive transport; patient oriented research; pharmacokinetics; sclera; therapy adverse effect; therapy design /development; uveitis

The existing methods to treat posterior eye diseases are intravitreal and periocular injections or systemic drug administration. Posterior eye diseases such as posterior uveitis, endophthalmitis, and age-related macular degeneration affect more than a million people in the United States each year. Systemic administration for the treatments of posterior eye diseases is usually not preferred because of the systemic toxicity encountered. Intravitreal and periocular injections are more effective routes of administration to treat posterior eye diseases compared with systemic drug delivery, but repeated injections cause side effects such as pain, intraocular bleeding, increased chances for infection, and the possibility of retinal detachment. Ocular injections also involve high health care cost because of the participation of experienced ophthalmologists in carrying out the treatments. An effective low-cost robust non-invasive drug delivery system for the treatments of posterior eye diseases has yet to be developed. There is also a lack of human pharmacokinetic data of ocular drug delivery in general. Ocular iontophoresis is a noninvasive method and has potential for drug delivery to the posterior of the eye. However, the mechanisms of ocular iontophoresis are not well understood, and there is much room for significant improvement of ocular iontophoretic drug delivery from the standpoint of the physical chemistry of ion transport and engineering. Also, the development of a non-invasive approach to study ocular drug pharmacokinetics in the posterior of the eye will be beneficial in ocular drug delivery research. The main objectives of the present project are (a) to characterize the transport properties of ocular iontophoresis and develop a more effective iontophoresis method for the treatment of posterior eye disease and (b) to develop magnetic resonance imaging (MRI) for ocular pharmacokinetic studies and perform these studies following ocular drug delivery such as iontophoresis. The project will be led by scientists in pharmaceutics and pharmaceutical chemistry (S.K. Li, College of Pharmacy, University of Utah), physics and radiology (E-K. Jeong, Utah Center for Advanced Imaging Research) and ophthalmology (P.S. Bernstein, Moran Eye Center). The information obtained in the present proposal will provide a knowledge base that allows pharmaceutical scientists to improve ocular iontophoresis and other drug delivery systems. It will be a great benefit to the public if an effective drug delivery system such as ocular iontophoresis can replace injections and systemic administration for drug delivery to the back of the eye.

现有的治疗眼后部疾病的方法有玻璃体内和眼周注射或全身用药。眼后部疾病，如后葡萄膜炎、眼内炎和老年性黄斑变性，每年影响美国100多万人。全身给药治疗眼后部疾病通常不是首选，因为会遇到全身毒性。与全身给药相比，玻璃体内和眼周注射是治疗后部眼部疾病的更有效的给药途径，但重复注射会引起副作用，如疼痛、眼内出血、感染机会增加和视网膜脱离的可能性。由于有经验的眼科医生参与进行治疗，眼部注射也涉及较高的医疗费用。用于治疗眼后部疾病的有效、低成本、健壮的非侵入性给药系统尚未开发出来。总体上也缺乏眼部给药的人体药代动力学数据。眼部离子导入是一种非侵入性的方法，有可能将药物输送到眼后。然而，眼部离子导入的机制还不是很清楚，从离子传输的物理化学和工程学的角度来看，眼部离子导入药物释放还有很大的改善空间。此外，发展一种非侵入性的方法来研究眼部药物在眼后的药代动力学，将有利于眼部药物释放的研究。本项目的主要目标是(A)描述眼部离子导入的传输特性，并开发一种更有效的治疗眼后部疾病的离子导入方法；(B)开发用于眼部药代动力学研究的磁共振成像(MRI)，并在离子导入等眼部给药后进行这些研究。该项目将由药剂学和药物化学(犹他大学药学院)、物理和放射学(E-K)的科学家领导。Jong，犹他州高级成像研究中心)和眼科(P.S.Bernstein，莫兰眼科中心)。本提案中获得的信息将提供一个知识库，使制药科学家能够改进眼部离子导入和其他药物输送系统。如果一种有效的药物释放系统，如眼部离子导入，能够取代注射和全身给药，用于眼后给药，将为公众带来极大的好处。